Granalix Bio Technologies Ltd.

As a startup biotechnology company, Granalix is dedicated to advancing the field of healthcare through innovation and cutting-edge research. Founded by two renowned professors, Prof. Ruth Gabizon from the Neurology Department of the Hadassah Medical Center and Prof. Shlomo Magdassi from the Casali Institute of Chemistry of The Hebrew University, Granalix represents the culmination of their combined experience and knowledge. Specializing in the development of biotechnology products, Granalix is committed to producing innovative solutions that address the most pressing healthcare challenges facing society today. The company's flagship product, Granagard, is the result of extensive research and development, and is poised to revolutionize the way we approach healthcare. As a startup, Granalix operates under the umbrella of Hadasit and Yissum, the technology transfer companies of Hadassah Medical Center and the Hebrew University of Jerusalem. This unique partnership allows the company to leverage the resources and expertise of two of the world's leading healthcare institutions, enabling it to accelerate its research and development efforts and bring new products to market more quickly. At Granalix, we are driven by a deep passion for improving healthcare outcomes and enhancing quality of life for people around the world. We are committed to pushing the boundaries of biotechnology and developing innovative solutions that have the potential to transform the field of healthcare as we know it.